Indications and uses
Temporarily relieves nasal congestion due to: Common cold Hay fever Upper respiratory allergies Shrinks swollen nasal membranes so you can breathe more freely
Temporarily relieves nasal congestion due to: Common cold Hay fever Upper respiratory allergies Shrinks swollen nasal membranes so you can breathe more freely
Adults and children 6 to 12 years of age (with adult supervision): 2 or 3 sprays in each nostril not more often than every 10 to 12 hours. Do not exceed 2 doses within any 24-hour period. Children under 6 years of age: Ask a doctor. Shake well before use. Before using for the first time remove the protective cap from the tip and prime metered pump by depressing pump firmly several times. To spray, hold bottle with...
store between 20°-25°C (68°-77°F) retain carton for future reference on full labeling
Oxymetazoline hydrochloride 0.05%
Nasal Decongestant
symptoms persist.
ask a health professional before use.
If swallowed, get medical help or contact a Poison Control Center right away.
Shake well before use. Before using for the first time remove the protective cap from the tip and prime metered pump by depressing pump firmly several times. To spray, hold bottle with thumb at base and nozzle between first and second fingers. Without tilting head, insert nozzle into nostril. Fully depress rim with a firm, even stroke and sniff deeply. Wipe nozzle clean after each use.
Benzalkonium Chloride, Edetate Disodium, Polyethylene Glycol, Povidone, Propylene GLycol, Purified Water, Sodium Phosphate Dibasic, Sodium Phosphate Monobasic.
SAFETY SEALED: DO NOT USE IF IMPRINTED SEAL ON BOTTLE IS BROKEN OR MISSING.
*This product is not manufactured or distributed by MSD Consumer Care, INC., distributor of Afrin.
Distributed By:
Chain Drug Consortium
3301 NW Boca Raton Blvd, Suite 101
Boca Raton, FL 33431
Made in USA
If for any reason you are not satisfied with this product, please return it to the store where purchased for a full refund.
*Compare to the active ingredient in Afrin Original Nasal Spray
Premier Value
Nasal Decongestant
Sinus Nasal Spray
Oxymetazoline HCl 0.05%
REGULAR STRENGTH
Fast, Powerful COngestion Relief
1 FL OZ (30 mL)
| Class | Version | Type | Effective |
|---|---|---|---|
| OXYMETAZOLINE Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 726062af-1135-4707-a1d7-57256991bbf9 | Product name | 2 | 20250226 |
| e67be450-f8e4-4bc1-88bd-1259d379f55f | Product name | 1 | 20210127 |
| c53f3286-4062-4cf5-8355-399519c639a6 | Product name | 1 | 20170424 |
| a993dfc5-f219-4460-bde6-30dd724d9ef0 | Product name | 1 | 20160818 |
| 19c71a3d-ed9c-166b-a7e5-38c250c35631 | Product name | 1 | 20140508 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 68016-316-03 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-2224-f424-e053-dadaa90a57ce | Nasal Spray |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 68016-316-03 | Nasal DecongestantPremier Value | 1 in 1 CARTON | SPRAY | 1 | 2 | |
| 68016-316-03 | Nasal DecongestantPremier Value | 30 mL in 1 BOTTLE, SPRAY | SPRAY | 30 | 2 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 68016-316-03 | ML - Milliliter | 68016-316 | 69a92eb9-ac7c-4bdd-8f45-9f4159702f1e | 1 | 2022-06-06 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| OXYMETAZOLINE HYDROCHLORIDE | ACTIVE INGREDIENT | K89MJ0S5VY | 2 | |
| OXYMETAZOLINE | ACTIVE MOIETY | 8VLN5B44ZY | 2 | |
| BENZALKONIUM CHLORIDE | INACTIVE INGREDIENT | F5UM2KM3W7 | 2 | |
| EDETATE DISODIUM | INACTIVE INGREDIENT | 7FLD91C86K | 2 | |
| POLYETHYLENE GLYCOLS | INACTIVE INGREDIENT | 3WJQ0SDW1A | 2 | |
| POVIDONE | INACTIVE INGREDIENT | FZ989GH94E | 2 | |
| PROPYLENE GLYCOL | INACTIVE INGREDIENT | 6DC9Q167V3 | 2 | |
| SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | INACTIVE INGREDIENT | 22ADO53M6F | 2 | |
| SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS | INACTIVE INGREDIENT | KH7I04HPUU | 2 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 68016-316 | 68016-316-03 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| OXYMETAZOLINE HYDROCHLORIDE | K89MJ0S5VY | ACTIB |
| BENZALKONIUM CHLORIDE | F5UM2KM3W7 | IACT |
| EDETATE DISODIUM | 7FLD91C86K | IACT |
| POLYETHYLENE GLYCOLS | 3WJQ0SDW1A | IACT |
| POVIDONE | FZ989GH94E | IACT |
| PROPYLENE GLYCOL | 6DC9Q167V3 | IACT |
| WATER | 059QF0KO0R | IACT |
| SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | IACT |
| SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS | KH7I04HPUU | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | GEL / TRANSDERMAL | 1 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | FILM, SOLUBLE / BUCCAL | 5 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SHAMPOO / TOPICAL | 8 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SPRAY / SUBLINGUAL | 36 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SPRAY / NASAL | 1 mg | ||
| POVIDONE | POVIDONE | FZ989GH94E | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, EXTENDED RELEASE / ORAL | 9 mg | ||
| SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | INJECTION, SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | 8 mg | ||
| POVIDONE | POVIDONE | FZ989GH94E | CAPSULE, COATED PELLETS / ORAL | 10.03 mg | ||
| SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS | SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS | KH7I04HPUU | INJECTION / INTRAMUSCULAR | 13 mg | ||
| SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS | SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS | KH7I04HPUU | SUSPENSION / OPHTHALMIC | 0.65 %w/w | ||
| POVIDONE | POVIDONE | FZ989GH94E | IMPLANT / SUBCUTANEOUS | 6 mg | ||
| SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS | SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS | KH7I04HPUU | INJECTION, SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | 8 mg | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SUSPENSION / AURICULAR (OTIC) | 0.01 %w/v | ||
| POVIDONE | POVIDONE | FZ989GH94E | TROCHE / ORAL | 30 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | GEL / OPHTHALMIC | 396 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SOLUTION / ORAL | 432 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SYSTEM / IONTOPHORESIS | 0.1 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | INJECTION, SUSPENSION / INTRAMUSCULAR | 1 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | DROPS / ORAL | 200 mg/1ml | ||
| SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | CAPSULE / ORAL | 40 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SHAMPOO, SUSPENSION / TOPICAL | 2 %w/w | ||
| SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS | SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS | KH7I04HPUU | TABLET / ORAL | 4.18 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | CREAM / VAGINAL | 3 mg | ||
| SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS | SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS | KH7I04HPUU | SOLUTION / ORAL | 120 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | AEROSOL, FOAM / TOPICAL | 0.05 %w/w | ||
| SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS | SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS | KH7I04HPUU | SOLUTION/ DROPS / OPHTHALMIC | 0.46 %w/v | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | GEL / OPHTHALMIC | 0.01 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SYSTEM / TOPICAL | 4200 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 19 mg | ||
| POVIDONE | POVIDONE | FZ989GH94E | TABLET, ORALLY DISINTEGRATING / ORAL | 15.03 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION, CONCENTRATE / INTRAVENOUS | 50.33 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION/ DROPS / OPHTHALMIC | 0.75 %w/v | ||
| SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS | SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS | KH7I04HPUU | SOLUTION / AURICULAR (OTIC) | 0.13 %w/w | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SPRAY, METERED / NASAL | 1 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SYRUP / ORAL | 40 mg | ||
| SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS | SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS | KH7I04HPUU | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 18.81 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | TABLET, EFFERVESCENT / ORAL | 32 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SYSTEM / TOPICAL | 126 mg | ||
| SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS | SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS | KH7I04HPUU | INJECTION, SUSPENSION / SOFT TISSUE | 13 mg | ||
| POVIDONE | POVIDONE | FZ989GH94E | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 17 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | GEL / TOPICAL | 4522 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | LIQUID / ORAL | 29008 mg | ||
| SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | INJECTION / INTRA-ARTICULAR | 28 mg | ||
| SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | TABLET, FOR SUSPENSION / ORAL | 60 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUPPOSITORY / VAGINAL | 252 mg | ||
| SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | OINTMENT / TOPICAL | 1 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | AEROSOL, FOAM / RECTAL | 1214 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | TABLET, FILM COATED / ORAL | 4 mg | ||
| SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | SPRAY, METERED / NASAL | 7 mg | ||
| SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | SOLUTION / INTRAVENOUS | 381 mg | ||
| POVIDONE | POVIDONE | FZ989GH94E | TABLET / ORAL | 216 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CAPSULE, EXTENDED RELEASE / ORAL | 8 mg | ||
| POVIDONE | POVIDONE | FZ989GH94E | TABLET, DELAYED RELEASE / ORAL | 53 mg | ||
| SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS | SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS | KH7I04HPUU | INSERT / INTRAOCULAR | 0.01 mg | ||
| SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | LOZENGE / TRANSMUCOSAL | 112 mg | ||
| SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | FILM / BUCCAL | 0.35 mg | ||
| POVIDONE | POVIDONE | FZ989GH94E | INJECTION / INTRAMUSCULAR | 0.2 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CAPSULE, DELAYED RELEASE / ORAL | 1.7 mg | ||
| SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS | SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS | KH7I04HPUU | FILM / BUCCAL | 1.09 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 63288e79-a3e5-4bab-81bc-a9f75da224f4 | d0d08381-4745-452b-8d58-b70d67f3a329 | 2015-10-14 | Warnings | 63288e79-a3e5-4bab-81bc-a9f75da224f4 d0d08381-4745-452b-8d58-b70d67f3a329 |
Adverse event summaries are temporarily unavailable. Other product information remains available.